Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14662076 | 0.76 | LPL (0.41) | LPLLIPGEGFRSNCA | |
| SCHEMBL584307 | 0.75 | LPL (0.40) | LPLLIPGALPLPDGFRBKDR | |
| SCHEMBL167417 | 0.73 | ALPL (0.57) | LPLLIPGALPLPDGFRBKDR | |
| SCHEMBL5314113 | 0.72 | LPL (0.47) | LPLLIPG | |
| SCHEMBL30198644 | 0.72 | ALPL (0.42) | LPLLIPGALPLPDGFRBKDR | |
| SCHEMBL17421093 | 0.72 | ALPL (0.42) | LPLLIPGALPLPDGFRBKDR | |
| SCHEMBL25112333 | 0.71 | IRAK4 (0.41) | LPLLIPGALPLPDGFRBKDR | |
| SCHEMBL583512 | 0.71 | LPL (0.40) | LPLLIPGALPLPDGFRBKDR | |
| SCHEMBL14926830 | 0.71 | ALPL (0.42) | LPLLIPGALPLPDGFRBKDR | |
| SCHEMBL945212 | 0.71 | BRD4 (0.42) | LPLLIPGALPLPDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-12060365-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-08-13 | — | — | US | disclosed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-09 | — | — | US | disclosed |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-09 | — | — | US | disclosed |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-02 | — | — | US | disclosed |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-02 | — | — | US | disclosed |
| WO-2021249913-A9 | 2'-(QUINOLIN-3-YL)-5',6'-DIHYDROSPIRO[AZETIDINE-3,4'-PYRROLO[1,2-B]PYRAZOLE]-1-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS MAP4K1 (HPK1) INHIBITORS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-03 | — | — | WO | disclosed |
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Marck Sharp & Dohme Corp. (US) | 2018-06-28 | — | — | US | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170369487-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-12-28 | — | — | US | disclosed |
| US-9695168-B2 | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160009712-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| WO-2016007731-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
| US-9149465-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | LPL 420/4885LIPG 783/4885ALPL 1216/4885 |
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MEN1, MLLT3 | LPL 4808/4885LIPG 4865/4885ALPL 4871/4885 |
| US-20170369487-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM5A, KDM1A, KDM1B | LPL 4359/4885LIPG 4054/4885ALPL 2949/4885 |
| US-20160009712-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM5A, KDM1A, KDM1B | LPL 4146/4885LIPG 3962/4885ALPL 3560/4885 |
| US-12060365-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MEN1, MLLT3 | LPL 4808/4885LIPG 4865/4885ALPL 4871/4885 |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ALPI, GAA, ZFX | LPL 136/4885LIPG 937/4885ALPL 15/4885 |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | LPL 4619/4885LIPG 4254/4885ALPL 3167/4885 |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | LPL 4808/4885LIPG 4865/4885ALPL 4871/4885 |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MLLT3, PRMT6 | LPL 4593/4885LIPG 4730/4885ALPL 4852/4885 |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | LPL 4808/4885LIPG 4865/4885ALPL 4871/4885 |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | LPL 4619/4885LIPG 4254/4885ALPL 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.